Cilofexor - Gilead Sciences/Phenex Pharmaceuticals
Alternative Names: CILO; GS-9674; LBO-03Latest Information Update: 16 Aug 2023
At a glance
- Originator Phenex Pharmaceuticals
- Developer Gilead Sciences
- Class Anti-inflammatories; Carboxylic acids; Hepatoprotectants; Nonsteroidal anti-inflammatories; Oxazoles; Pyridines; Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Primary sclerosing cholangitis
- Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- No development reported Primary biliary cirrhosis
Most Recent Events
- 21 Jun 2023 Efficacy, adverse events and pharmacodynamics data from a phase III trial in Primary sclerosing cholangitis presented at the European Association for the Study of the Liver Congress (EASL-2023)
- 20 Jan 2023 Gilead Sciences terminates phase III trial in Primary sclerosing cholangitis (In adults, In the elderly) in USA, Canada, Austria, United Kingdom, Switzerland, Spain, New Zealand, Japan, Italy, Italy, Israel, Germany, France, Finland, Denmark, Belgium and Australia (PO), owing to the low probability of achieving its primary end point (NCT03890120)
- 04 Nov 2022 Pharmacodynamics data from a phase II ATLAS trial in Nonalcoholic steatohepatitis presented at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2022)